Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.

Hurt AC, Ho HT, Barr I.

Expert Rev Anti Infect Ther. 2006 Oct;4(5):795-805. Review.

PMID:
17140356
2.

Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries.

Barr IG, Deng YM, Iannello P, Hurt AC, Komadina N.

Antiviral Res. 2008 Nov;80(2):200-5. doi: 10.1016/j.antiviral.2008.06.008. Epub 2008 Jul 9.

PMID:
18611414
3.
4.

Antiviral drugs for influenza.

[No authors listed]

Med Lett Drugs Ther. 2011 Jan 10;53(1355):1-3. No abstract available.

PMID:
21212742
5.

Drug resistance among influenza A viruses isolated in Italy from 2000 to 2005: are the emergence of Adamantane-resistant viruses cause of concern?

Ansaldi F, Valle L, Amicizia D, Banfi F, Pastorino B, Sticchi L, Icardi G, Gasparini R, Crovari P.

J Prev Med Hyg. 2006 Mar;47(1):1-3. No abstract available.

PMID:
17061402
6.

Anti-influenza drugs and neuraminidase inhibitors.

Roberts NA.

Prog Drug Res. 2001;56:195-237. Review.

PMID:
11417114
7.

[Research progress of neuraminidase inhibitors for anti-influenza].

Liu AL, Wang HD, Yang F, Du GH.

Yao Xue Xue Bao. 2009 Sep;44(9):935-42. Review. Chinese.

PMID:
20055166
8.

Antivirals used for influenza chemoprophylaxis.

Tsiodras S, Nikolopoulos G, Bonovas S.

Curr Med Chem. 2012;19(35):5947-56. Review.

PMID:
22963557
9.

Antivirals and influenza: frequency of resistance.

Monto AS.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S110-2. doi: 10.1097/INF.0b013e318168b739.

PMID:
18820569
10.

Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus.

Rungrotmongkol T, Intharathep P, Malaisree M, Nunthaboot N, Kaiyawet N, Sompornpisut P, Payungporn S, Poovorawan Y, Hannongbua S.

Biochem Biophys Res Commun. 2009 Jul 31;385(3):390-4. doi: 10.1016/j.bbrc.2009.05.066. Epub 2009 May 20.

PMID:
19463784
11.

Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.

Barr IG, Hurt AC, Iannello P, Tomasov C, Deed N, Komadina N.

Antiviral Res. 2007 Feb;73(2):112-7. Epub 2006 Aug 28.

PMID:
16963130
12.

Use of neuraminidase inhibitors to combat pandemic influenza.

Democratis J, Pareek M, Stephenson I.

J Antimicrob Chemother. 2006 Nov;58(5):911-5. Epub 2006 Sep 6.

PMID:
16956904
13.

Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

Nguyen HT, Fry AM, Gubareva LV.

Antivir Ther. 2012;17(1 Pt B):159-73. doi: 10.3851/IMP2067. Epub 2012 Feb 3. Review.

PMID:
22311680
14.

Rational development of neuraminidase inhibitor as novel anti-flu drug.

Chintakrindi A, D'souza C, Kanyalkar M.

Mini Rev Med Chem. 2012 Oct;12(12):1273-81. Review.

PMID:
22512586
15.

Antiviral management of seasonal and pandemic influenza.

Hayden FG, Pavia AT.

J Infect Dis. 2006 Nov 1;194 Suppl 2:S119-26.

PMID:
17163384
16.

Antivirals for influenza: strategies for use in pediatrics.

Smith SM, Gums JG.

Paediatr Drugs. 2010 Oct 1;12(5):285-99. doi: 10.2165/11532530-000000000-00000. Review.

PMID:
20799758
17.

Anti-influenza drugs and neuraminidase inhibitors.

Roberts NA.

Prog Drug Res. 2001;Spec No:35-77. Review.

PMID:
11548210
18.

Neuraminidase inhibitors and their role in avian and pandemic influenza.

Crusat M, de Jong MD.

Antivir Ther. 2007;12(4 Pt B):593-602. Review.

PMID:
17944267
19.

Influenza virus resistance to antiviral therapy.

van der Vries E, Schutten M, Fraaij P, Boucher C, Osterhaus A.

Adv Pharmacol. 2013;67:217-46. doi: 10.1016/B978-0-12-405880-4.00006-8. Review.

PMID:
23886002
20.

A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.

Oxford J, Balasingam S, Lambkin R.

J Antimicrob Chemother. 2004 Feb;53(2):133-6. Epub 2003 Dec 19. Review.

PMID:
14688047

Supplemental Content

Support Center